Search company, investor...
Xceleron company logo


Founded Year



Acquired | Acquired

Total Raised


About Xceleron

Xceleron is a contract research organization and Accelerator Mass Spectrometry (AMS) specialist for pharmaceutical, food technology, and crop protection applications. The AMS platform developed at Xceleron has sensitivity and features that allow identification and analysis of therapeutically and biologically relevant entities, including small molecules to large molecules at low concentrations. With this, Xceleron has supported regulatory filings for dozens of marketed drugs since 1998. The technology has been developed to support discovery of novel biomarkers and potentially new disease-modifying targets.

Headquarters Location

20340 Seneca Meadows Parkway

Germantown, Maryland, 20876,

United States


Missing: Xceleron's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Xceleron's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Xceleron Patents

Xceleron has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Mass spectrometry, Analytical chemistry, Spectroscopy, Chromatography, Ion source


Application Date


Grant Date



Related Topics

Mass spectrometry, Analytical chemistry, Spectroscopy, Chromatography, Ion source



Latest Xceleron News

Xceleron quits York bases in move to US

Jul 17, 2020

Menu By Julie Hayes XCELERON, the York pharmaceutical company, is moving its operations to the United States after going into administration. The business, which was founded in 1997 as a spin-off of the University of York , was sold in a pre-pack administration to its existing management team and venture capital investors and will continue to operate from its laboratory in Germantown, Maryland. The business, which employed about 20 people over three sites at York Science Park and FERA in Sand Hutton, will continue to employ four people in client meeting roles such as project managers and its chief scientific officer. Mike Butler, chief executive of the company, which uses nanotechnology to accelerate drug development, said: “Some of them are in the process of looking for other jobs and some are hoping to transfer to the States as well. “We are going to continue to run the business in the United States, simply because we have a much newer facility there. Our site in York is perfect for a start-up but at this stage in the company’s development, being based in three buildings is not ideal.” He said the company was affected by the state of the economy and sales didn’t support keeping all of its premises. Its existing venture-capital investors Albion Ventures and Solon Ventures have invested a further $2.4 million to help the company relocate and invest in staff and equipment in the US, which is expected to be completed by the end of March. He said: “The value proposition everybody sees in the company hasn’t changed. It’s a question of where is the best place for us to efficiently run the business. One of the challenges we had when it came to making that decision was that we weren’t in one facility in York, but in three buildings in two locations.” A spokesman for the University of York said: “While we are disappointed that Xceleron is scaling back its UK operation, we are pleased that the business is continuing and will still be in a position to deliver the benefits to the pharmaceutical industry we originally anticipated. The fact that some jobs are being retained in the UK is also welcome. In due course, we hope that, once the momentum has returned to the pharmaceuticals market, Xceleron can resume its UK operation at its previous level.”

Xceleron Frequently Asked Questions (FAQ)

  • When was Xceleron founded?

    Xceleron was founded in 1997.

  • Where is Xceleron's headquarters?

    Xceleron's headquarters is located at 20340 Seneca Meadows Parkway, Germantown.

  • What is Xceleron's latest funding round?

    Xceleron's latest funding round is Acquired.

  • How much did Xceleron raise?

    Xceleron raised a total of $4.92M.

  • Who are the investors of Xceleron?

    Investors of Xceleron include Pharmaron, Solon Ventures, Albion Capital, Frog Capital and York University.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.